Terms: = Thyroid cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
202 results:
1. Correlation between ferroptosis and adriamycin resistance in breast cancer regulated by transferrin receptor and its molecular mechanism.
Yu X; Cheng L; Liu S; Wang M; Zhang H; Wang X; Zhang H; Yang Z; Wu S
FASEB J; 2024 Mar; 38(5):e23550. PubMed ID: 38466338
[TBL] [Abstract] [Full Text] [Related]
2. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
Wang J; Xia YC; Tian BX; Li JT; Li HY; Dong H; Li XG; Yu H; Zhu YY; Ma J; Jiang YJ; Jin GZ
Cancer; 2024 Apr; 130(S8):1424-1434. PubMed ID: 38217532
[TBL] [Abstract] [Full Text] [Related]
3. Contrast-Enhanced Ultrasound and Conventional Ultrasound Characteristics of Breast cancer With Different Molecular Subtypes.
Li X; Zhang J; Zhang G; Liu J; Tang C; Chen K; Chen P; Tan L; Guo Y
Clin Breast Cancer; 2024 Apr; 24(3):204-214. PubMed ID: 38102010
[TBL] [Abstract] [Full Text] [Related]
4. Neutrophil extracellular traps and neutrophil-related mediators in human thyroid cancer.
Modestino L; Cristinziano L; Poto R; Ventrici A; Trocchia M; Ferrari SM; Fallahi P; Paparo SR; Marone G; Antonelli A; Varricchi G; Galdiero MR
Front Immunol; 2023; 14():1167404. PubMed ID: 37705974
[TBL] [Abstract] [Full Text] [Related]
5. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
6. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
[TBL] [Abstract] [Full Text] [Related]
7. A Shift in Molecular Drivers of Papillary thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
[TBL] [Abstract] [Full Text] [Related]
8. Nomogram for preoperative estimation risk of lateral cervical lymph node metastasis in papillary thyroid carcinoma: a multicenter study.
Zhu J; Chang L; Li D; Yue B; Wei X; Li D; Wei X
Cancer Imaging; 2023 Jun; 23(1):55. PubMed ID: 37264400
[TBL] [Abstract] [Full Text] [Related]
9. Cribriform Morular thyroid Carcinoma - Ultimobranchial Pouch-Related? Deep Molecular Insights of a Unique Case.
Dettmer MS; Hürlimann S; Scheuble L; Vassella E; Perren A; Wicke C
Endocr Pathol; 2023 Sep; 34(3):342-348. PubMed ID: 37249797
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of serum B7-H3 expression, ultrasound and clinical characteristics to predict the risk of cervical lymph node metastases in papillary thyroid carcinoma by nomogram.
Huang Y; Huang Z; Cai H; Zhuge L; Wang S; Yan D; Zhang X; An C; Niu L; Li Z
J Clin Lab Anal; 2023 Jan; 37(1):e24811. PubMed ID: 36525343
[TBL] [Abstract] [Full Text] [Related]
11. Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours.
Savari O; Febres-Aldana C; Chang JC; Fanaroff RE; Ventura K; Bodd F; Paik P; Vundavalli M; Saqi A; Askin FB; Travis WD; Rekhtman N
Histopathology; 2023 Jan; 82(2):242-253. PubMed ID: 36130728
[TBL] [Abstract] [Full Text] [Related]
12. A pH/H
Cheng P; Cheng L; Han H; Li J; Ma C; Huang H; Zhou J; Feng J; Huang Y; Lv Y; Huang H; Wang Y; Hou L; Chen Y; Li G
Adv Healthc Mater; 2022 Nov; 11(22):e2200971. PubMed ID: 36056927
[TBL] [Abstract] [Full Text] [Related]
13. Indeterminate thyroid Fine-Needle Aspirations in Pediatrics: Exploring Clinicopathologic Features and Utility of Molecular Profiling.
Baran JA; Halada S; Bauer AJ; Ricarte-Filho JC; Isaza A; Surrey LF; McGrath C; Bhatti T; Jalaly J; Mostoufi-Moab S; Franco AT; Adzick NS; Kazahaya K; Cahill AM; Baloch Z
Horm Res Paediatr; 2022; 95(5):430-441. PubMed ID: 35871517
[TBL] [Abstract] [Full Text] [Related]
14. Search for New Target Genes of MicroRNA for Differential Diagnosis of Benign and Malignant Neoplasms of the thyroid Gland by In Silico Methods.
Kononchuk VV; Kopeikina EV; Kalinina TS; Saik OV; Alekseenok EY; Kolyagina MK; Matashova VA; Shevchenko SP; Gulyaeva LF; Kushlinskii NE
Bull Exp Biol Med; 2022 Jun; 173(2):246-251. PubMed ID: 35737153
[TBL] [Abstract] [Full Text] [Related]
15. Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma.
Zhang Z; Xia F; Xu Z; Peng J; Kang F; Li J; Zhang W; Hong Q
Sci Rep; 2022 May; 12(1):8886. PubMed ID: 35614201
[TBL] [Abstract] [Full Text] [Related]
16. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract] [Full Text] [Related]
17. Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1-mediated TOP2A/PI3K/AKT axis.
Bao ZM; Yao D; Qian X; Zhang HG; Yang M; Guo YH; Qin L
Kaohsiung J Med Sci; 2022 Jul; 38(7):662-674. PubMed ID: 35394699
[TBL] [Abstract] [Full Text] [Related]
18. Stress, thyroid Dysregulation, and thyroid cancer in Children and Adolescents: Proposed Impending Mechanisms.
Kyriacou A; Tziaferi V; Toumba M
Horm Res Paediatr; 2023; 96(1):44-53. PubMed ID: 35385843
[TBL] [Abstract] [Full Text] [Related]
19. Long non-coding ROR promotes the progression of papillary thyroid carcinoma through regulation of the TESC/ALDH1A1/TUBB3/PTEN axis.
Fan Y; Fan X; Yan H; Liu Z; Wang X; Yuan Q; Xie J; Lu X; Yang Y
Cell Death Dis; 2022 Feb; 13(2):157. PubMed ID: 35173149
[TBL] [Abstract] [Full Text] [Related]
20. Ezh2 promotes TRβ lysine methylation-mediated degradation in hepatocellular carcinoma.
Park SC; Lee JM
Genes Genomics; 2022 Mar; 44(3):369-377. PubMed ID: 34851506
[TBL] [Abstract] [Full Text] [Related]
[Next]
